Disease control over time in the patient described in the case study.
| Outcome | Baseline | Etanercept | Rituximab | |||
|---|---|---|---|---|---|---|
| Month 1 | Month 2 | Year 2 | Month 1 | Month 2 | ||
| Joints | ||||||
| Swollen | 4 | — | 0 | 6 | 2 | 1 |
| Tender | 7 | — | 2 | 10 | 3 | 2 |
| Global assessment | ||||||
| Patient | 6 | 4 | 2 | 6 | 4 | 3 |
| Physician | 5 | 3 | 1 | 5 | 3 | 2 |
| CDAI | 23 | 13 | 5 | 27 | 12 | 8 |
| Laboratory values | ||||||
| CRP, mg/dl | 1.5 | 0.8 | 0.6 | 1.2 | — | 0.8 |
| RF, units | 128 | |||||
| CCP, units | 85 | |||||
| SDAI | 24.5 | 13.8 | 5.6 | 28.5 | — | 8.8 |
| DAS28 | 4.94 | 3.77 | 2.73 | 5.18 | — | 3.24 |
CDAI: Clinical Disease Activity Index; CRP: C-reactive protein; DAS28: 28-joint Disease Activity Score; RF: rheumatoid factor; SDAI: Simplified Disease Activity Index; CCP: citric citrullinated peptide antibody.